GeneralBullishFortune Crypto · 5h ago7/10
📰
Novo Nordisk CEO looks beyond weight loss to longevity and aesthetics
Novo Nordisk is expanding the perceived applications of semaglutide beyond weight loss, with emerging data suggesting the drug may influence biological aging processes. This pivot reflects pharmaceutical industry interest in longevity markets and positions the company to capture value across multiple therapeutic categories.
